Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.
Gravestock P, Clark E, Morton M, Sharma S, Fisher H, Walker J, Wood R, Hancock H, Waugh N, Cooper A, Maier R, Marshall J, Chandler R, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R.
Gravestock P, et al.
NIHR Open Res. 2023 Jan 10;2:49. doi: 10.3310/nihropenres.13284.2. eCollection 2022.
NIHR Open Res. 2023.
PMID: 37035713
Free PMC article.